Physician profile
Asjad Khan
NPI 1265444715
$1,431.59
in general payments reported to CMS, 2019-2025
31 companies · $586 in 2025
The $586 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $34.28 · 2022: $227 · 2023: $97.38 · 2024: $165 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $167.84 | 2022-2025 | Skytrofa |
| Abbvie INC. | $166.19 | 2019-2025 | |
| Soleno Therapeutics, INC. | $109.88 | 2025 | Vykat Xr |
| Radius Health, INC. | $100.41 | 2019 | |
| Tolmar, INC. | $92.44 | 2024-2025 | Fensolvi |
| Alexion Pharmaceuticals, INC. | $90.08 | 2019-2025 | Strensiq |
| Abbott Laboratories | $75.00 | 2023 | Freestyle Libre 3 |
| Pfizer INC. | $73.26 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $70.48 | 2025 | |
| Insulet Corporation | $57.01 | 2019-2022 | |
| Novo Nordisk INC | $46.03 | 2024-2025 | Sogroya |
| Sequel Med Tech, LLC | $31.70 | 2025 | Twiist |
| Arbor Pharmaceuticals, INC. | $30.65 | 2019 | |
| Sandoz INC. | $27.11 | 2025 | Omnitrope |
| Beta Bionics, INC. | $22.38 | 2023 | Ilet Bionic Pancreas |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leadiant Biosciences, INC. | $22.09 | 2024 | Cystaran |
| Sanofi-Aventis U.S. LLC | $20.30 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $19.74 | 2019 | |
| Endo USA, INC. | $19.21 | 2025 | Supprelin |
| Tandem Diabetes Care, INC. | $18.85 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $18.81 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $18.15 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.48 | 2024 | Triptodur |
| Lilly USA, LLC | $15.58 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.57 | 2019 | |
| Eton Pharmaceuticals, INC. | $15.19 | 2025 | Khindivi, Increlex, Alkindi |
| Lifescan, INC. | $14.96 | 2022 | |
| Mannkind Corporation | $14.64 | 2025 | |
| Mallinckrodt Enterprises LLC | $14.33 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $14.15 | 2022 | |
| Zealand Pharma US, INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asjad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.